A Clinical Study of HH-1270 in Healthy Chinese Subjects
A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HH-1270 Tablets in Healthy Chinese Participants
This study is a single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial to evaluate the safety and PK profile in healthy Chinese subjects.
調査の概要
詳細な説明
SAD consists of 6 prespecified dose levels. Participants are enrolled in cohorts according to the dose-escalation principle and randomized to receive HH-1270 tablets (A) or placebo (P). Higher dose cohorts may begin only after confirmation by the SRC for the lower dose cohort. This part aims to evaluate the safety, tolerability, PK, and PD characteristics of single-dose HH-1270. One dose cohort in the SAD phase will be selected for a food-effect exploration.
MAD consists of 4 prespecified dose levels. Each participant receives once-daily dosing under fasting conditions for 7 consecutive days and is randomized to receive HH-1270 tablets (A) or placebo (P). Higher dose cohorts may begin only after confirmation by the SRC for the lower dose cohort. This part aims to evaluate the safety, tolerability, PK, and PD characteristics of multiple-dose HH-1270.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Xiyu Zhang
- 電話番号:18701650516
- メール:zhangxiyu@hhhbio.com
研究場所
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100191
- 募集
- Peking University Third Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Healthy Chinese adults aged 18 to 55 years (inclusive), both male and female.
- Weight: male ≥50.0 kg, female ≥45.0 kg, and body mass index (BMI) 18.0 to 28.0 kg/m² (inclusive; BMI = weight/height²).
- Results of vital signs, physical examination, laboratory tests, and 12-lead electrocardiogram (ECG) at screening are normal or abnormal without clinical significance.
- Participants must agree to take adequate and effective contraceptive measures.
- Participants understand and comply with the study procedures, voluntarily participate, and sign the informed consent form (ICF).
Exclusion Criteria:
- Individuals with severe systemic diseases, infectious diseases, or mental disorders.
- Clinically significant electrocardiogram (ECG) abnormalities.
- History of clinically significant drug allergy or atopic allergic diseases.
- Comorbid conditions that may affect drug absorption, distribution, metabolism, excretion, and interpretation of safety data, or that may reduce compliance, including but not limited to any of the following.
- Positive results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or Treponema pallidum antibody (TPAb).
- History of drug abuse or alcoholism within 12 months before screening, or evidence of alcohol abuse or excessive drinking confirmed by an alcohol breath test at screening.
- Frequent use of tobacco or nicotine products (e.g., patches, gum, etc.) or any other smoking products within 30 days before screening.
- Blood donation ≥400 mL within 3 months before screening.
- Participation in another interventional clinical trial within 3 months before screening.
- Use of any prescription medication within 4 weeks or 5 half-lives (whichever is longer) before screening.
- Use of over-the-counter drugs, health supplements, herbal medicines, or traditional Chinese medicines, or use of medications that affect drug metabolism, within 2 weeks before screening.
- Known or suspected history of allergy to any component of HH-1270 tablets or their excipients.
- Inability to accept standardized diet management at the study center.
- Participants who are breastfeeding or have a positive pregnancy test before the first dose.
- Participants deemed unsuitable for participation in the study by the investigator.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:HH-1270 group
SAD groups will be received HH-1270 tablets from 5mg to 200mg once and MAD groups will be received HH-1270 tablets from 5 mg to 60 mg once per day for 7 days |
SAD groups will be received HH-1270 tablets from 5mg to 200mg once and MAD groups will be received HH-1270 tablets from 5 mg to 60 mg once per day for 7 days |
|
プラセボコンパレーター:Placebo group
SAD groups will be received HH-1270 placebo tablets from 5mg to 200mg once and MAD groups will be received HH-1270 placebo tablets from 5 mg to 60 mg once per day for 7 days |
SAD groups will be received placebo tablets from 5mg to 200mg once and MAD groups will be received HH-1270 placebo tablets from 5 mg to 60 mg once per day for 7 days |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of adverse events (AEs) and serious adverse events (SAEs)
時間枠:up to 15/21 days in SAD/MAD
|
Number of subjects with adverse events (AEs) and serious adverse events (SAEs) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v6.0. |
up to 15/21 days in SAD/MAD
|
|
Clinically significant abnormalities
時間枠:up to 14/21 days in SAD/MAD
|
Number of subjects with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v6.0. |
up to 14/21 days in SAD/MAD
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Area Under the Plasma Concentration Versus Time Curve (AUC)
時間枠:up to 8/14 days in SAD/MAD
|
AUC of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Maximum Plasma Concentration (Cmax)
時間枠:up to 8/14 days in SAD/MAD
|
Cmax of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Time to Reach Maximum Plasma Concentration (Tmax)
時間枠:up to 8/14 days in SAD/MAD
|
Tmax of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Apparent Terminal Elimination Half-life (T1/2)
時間枠:up to 8/14 days in SAD/MAD
|
T1/2 of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Apparent Plasma Clearance (CL/F)
時間枠:up to 8/14 days in SAD/MAD
|
CL/F of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Apparent volume of distribution(Vd/F)
時間枠:up to 8/14 days in SAD/MAD
|
Vd/F of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
To evaluate the TBA level
時間枠:up to 15/21 days in SAD/MAD
|
TBA level for each collection point |
up to 15/21 days in SAD/MAD
|
|
To evaluate the CP-1 level
時間枠:up to 15/21 days in SAD/MAD
|
CP-1 level for each collection point |
up to 15/21 days in SAD/MAD
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To evaluate QTc change
時間枠:up to 8 days in SAD
|
QTc values in each collection point |
up to 8 days in SAD
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- HH1270-101
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。